Navigation Links
Industry Executives Finding Value in Shift of Scientific Publications
Date:9/26/2007

CHAPEL HILL, N.C., Sept. 26 /PRNewswire/ -- The landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. Half of global publications groups are fully located in the marketing function, but publications leaders foresee a shift to medical groups to increase clinical presentation, according to a new report released by Best Practices, LLC.

In a benchmarking study that included such influential companies as Pfizer, GlaxoSmithKline, Lilly and Merck, it was found that 14 percent of participating pharmaceutical and biotech companies avoid using global or regional marketing representatives to develop their global publications strategy. These companies, which align publications strictly within the medical group, receive strategic input from medical directors, advisor physicians and biostatisticians.

For a complimentary summary of the full report "Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance," click on the following link http://www3.best-in-class.com/rr790.htm. The study guides pharmaceutical and biotechnology companies in the transition to the new publishing environment to create the desired synergy between credibility of scientific rigor and increased commercial success.

Other key topic areas in the research include:

-- Impact of transparency guidelines on publications, planning and

delivery

-- Tactics for handling publication of neutral or negative clinical trial

results

-- Optimal structure for the global publications function

-- Transition of global publication function from commercial to clinical

-- Strategy changes for the new marketplace

Among the key topics gathered in this report are:

-- Centralization of publications strategy, planning and delivery

-- Trends surrounding regional strategy contribution

-- Strategies for publishing neutral/negative results

-- Outsourcing of global publications resources

-- Measures used for performance evaluation

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr790.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian bio-industry should impress American investors
2. Failure of heart drug offers lessons for drug industry
3. Lesson for Wisconsin: Carolina tech industry took time to build
4. At 30, biotech is an industry at a crossroads
5. Wisconsin gets "biotech hotspot" designation from industry newsletter
6. Official touts biotech industry in Sheboygan visit
7. UW biotech program launches graduates into evolving industry (part 2)
8. UW biotech program launches graduates into evolving industry (part 1)
9. Midwest is key player for Biofuels industry
10. Take off: Canadian biotech industry thrives
11. TomoTherapy leads the industry in CT image-guided treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):